HOME › DRUGS › DACLIZUMAB
ACTIVE SUBSTANCE / INN

DACLIZUMAB

Brand name(s): ZINBRYTA, Zinbryta, Zenapax
FDA LISTED
EMA LISTED
PRESCRIPTION
WITHDRAWN
BLA761029
Graft Rejection;Kidney Transplantation
ACTIVE SUBSTANCE
Daclizumab
REGULATORS
FDA · EMA
SPONSORS / MAH
Roche Registration Ltd., BIOGEN, Biogen Idec Ltd
TOTAL APPLICATIONS
3
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
ZINBRYTABLA761029BIOGENPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
ZinbrytaBiogen Idec LtdWithdrawn01/07/2016Multiple Sclerosis
ZenapaxRoche Registration Ltd.Withdrawn26/02/1999Graft Rejection;Kidney Transplantation

FULL INTELLIGENCE ON DACLIZUMAB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →